2026-06-14T06:44:14Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/68762024-11-28T17:45:31Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16961

00925njm 22002777a 4500 dc Trickey, Adam author May, Margaret T author Vehreschild, Janne author Obel, Niels author Gill, Michael John author Crane, Heidi author Boesecke, Christoph author Samji, Hasina author Grabar, Sophie author Cazanave, Charles author Cavassini, Matthias author Shepherd, Leah author d'Arminio Monforte, Antonella author Smit, Colette author Saag, Michael author Lampe, Fiona author Hernando Sebastian, Victoria author Montero, Marta author Zangerle, Robert author Justice, Amy C author Sterling, Timothy author Miro, Jose author Ingle, Suzanne author Sterne, Jonathan A C author 2016-08-15 Objectives: To estimate mortality rates and prognostic factors in HIV-positive patients who started combination antiretroviral therapy between 1996-1999 and survived for more than ten years. Methods: We used data from 18 European and North American HIV cohort studies contributing to the Antiretroviral Therapy Cohort Collaboration. We followed up patients from ten years after start of combination antiretroviral therapy. We estimated overall and cause-specific mortality rate ratios for age, sex, transmission through injection drug use, AIDS, CD4 count and HIV-1 RNA. Results: During 50,593 person years 656/13,011 (5%) patients died. Older age, male sex, injecting drug use transmission, AIDS, and low CD4 count and detectable viral replication ten years after starting combination antiretroviral therapy were associated with higher subsequent mortality. CD4 count at ART start did not predict mortality in models adjusted for patient characteristics ten years after start of antiretroviral therapy. The most frequent causes of death (among 340 classified) were non-AIDS cancer, AIDS, cardiovascular, and liver-related disease. Older age was strongly associated with cardiovascular mortality, injecting drug use transmission with non-AIDS infection and liver-related mortality, and low CD4 and detectable viral replication ten years after starting antiretroviral therapy with AIDS mortality. Five-year mortality risk was <5% in 60% of all patients, and in 30% of those aged over 60 years. Conclusions: Viral replication, lower CD4 count, prior AIDS, and transmission via injecting drug use continue to predict higher all-cause and AIDS-related mortality in patients treated with combination antiretroviral therapy for over a decade. Deaths from AIDS and non-AIDS infection are less frequent than deaths from other non-AIDS causes. PLoS One. 2016 Aug 15;11(8):e0160460. 10.1371/journal.pone.0160460 1932-6203 PloS one 27525413 http://hdl.handle.net/20.500.12105/6876 Cause-Specific Mortality in HIV-Positive Patients Who Survived Ten Years after Starting Antiretroviral Therapy